These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. Pušnik J; König J; Mai K; Richter E; Zorn J; Proksch H; Schulte B; Alter G; Streeck H J Virol; 2022 Aug; 96(15):e0076022. PubMed ID: 35862718 [TBL] [Abstract][Full Text] [Related]
23. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA; Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598 [TBL] [Abstract][Full Text] [Related]
24. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children. Zhong Y; Kang AYH; Tay CJX; Li HE; Elyana N; Tan CW; Yap WC; Lim JME; Le Bert N; Chan KR; Ong EZ; Low JG; Shek LP; Tham EH; Ooi EE Nat Med; 2024 May; 30(5):1373-1383. PubMed ID: 38689059 [TBL] [Abstract][Full Text] [Related]
25. Diversification of the VH3-53 immunoglobulin gene segment by somatic hypermutation results in neutralization of SARS-CoV-2 virus variants. Bruhn M; Obara M; Salam A; Costa B; Ziegler A; Waltl I; Pavlou A; Hoffmann M; Graalmann T; Pöhlmann S; Schambach A; Kalinke U Eur J Immunol; 2024 Jul; 54(7):e2451056. PubMed ID: 38593351 [TBL] [Abstract][Full Text] [Related]
26. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
27. Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. Haralambieva IH; Monroe JM; Ovsyannikova IG; Grill DE; Poland GA; Kennedy RB J Infect Dis; 2022 Aug; 226(1):23-31. PubMed ID: 35137144 [TBL] [Abstract][Full Text] [Related]
28. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]
29. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G Front Immunol; 2021; 12():778679. PubMed ID: 34868051 [TBL] [Abstract][Full Text] [Related]
30. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes. Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935 [TBL] [Abstract][Full Text] [Related]
31. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H Front Immunol; 2021; 12():743422. PubMed ID: 34659239 [TBL] [Abstract][Full Text] [Related]
32. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. Lyski ZL; Brunton AE; Strnad MI; Sullivan PE; Siegel SAR; Tafesse FG; Slifka MK; Messer WB J Infect Dis; 2022 Mar; 225(6):947-956. PubMed ID: 34865053 [TBL] [Abstract][Full Text] [Related]
33. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410 [TBL] [Abstract][Full Text] [Related]
34. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. Brewer RC; Ramadoss NS; Lahey LJ; Jahanbani S; Robinson WH; Lanz TV Nat Immunol; 2022 Jan; 23(1):33-39. PubMed ID: 34848871 [TBL] [Abstract][Full Text] [Related]
35. mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection. Casado JL; Vizcarra P; Martín-Hondarza A; Gómez-Maldonado S; Muedra-Sánchez M; Del Pino J; Mirabella IG; Martín-Colmenarejo S; Haemmerle J; Fernández-Escribano M; Vallejo A Front Immunol; 2023; 14():1127379. PubMed ID: 37457694 [TBL] [Abstract][Full Text] [Related]
36. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648 [TBL] [Abstract][Full Text] [Related]
37. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191 [TBL] [Abstract][Full Text] [Related]
38. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K Front Immunol; 2022; 13():888794. PubMed ID: 35711424 [TBL] [Abstract][Full Text] [Related]
39. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
40. Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals. Luczkowiak J; Labiod N; Rivas G; Rolo M; Lasala F; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R J Infect Dis; 2022 Jun; 225(11):1905-1908. PubMed ID: 34963008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]